


## eXmoor Pharma and Siam Bioscience to establish leading cell & gene therapy services in Southeast Asia

24 September 2025 | News

The partnership aims to act as a platform to introduce international cell and gene therapies and technologies into the region



UK-based eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Thailand's Siam Bioscience, a leading biopharmaceutical company in ASEAN, have announced a strategic partnership to build the region's foremost centre for Cell and Gene Therapy (CGT) development and manufacturing.

The collaboration aims to stimulate and accelerate the growth of the CGT industry in Thailand and Southeast Asia. It will provide a comprehensive suite of services to support local innovation and attract global therapies and investment into the region. Based in Bangkok, the new offering will serve therapy developers working to deliver advanced medicines to patients more efficiently and in full regulatory compliance.

Cell and gene therapies (CGTs) represent the cutting edge of biotherapeutics, functioning as one-time medicines that use genetic materials and living cells to treat various severe and rare diseases, such as cancer and genetic diseases, at a molecular or cellular level.

Under the partnership, eXmoor will work jointly with Siam Bioscience to provide a full range of services including consultancy, process and analytical development, and GMP clinical and commercial manufacturing. These services will support CGT programmes developed in Thailand and Southeast Asia. The new centre will be located at Siam Bioscience's manufacturing site near Bangkok, with both companies contributing their respective expertise and infrastructure to the initiative.

The partnership also aims to act as a platform to introduce international cell and gene therapies and technologies into the region. This will give patients across Southeast Asia greater access to international standard CGT, while supporting the growth of sustainable healthcare systems in the region. By offering a regionally based but globally aligned manufacturing model, the collaboration aims to reduce delays, lower logistic burdens, and improve equity of access to transformative therapies.